Tech Company Financing Transactions
Flamingo Therapeutics Funding Round
On 6/17/2023, Flamingo Therapeutics raised $1.9 million in funding from Flanders Innovation and Entrepreneurship.
Transaction Overview
Company Name
Announced On
6/17/2023
Transaction Type
Venture Equity
Amount
$1,860,000
Round
Undisclosed
Investors
Flanders Innovation and Entrepreneurship (Lead Investor)
Proceeds Purpose
Funding from the grant will be used to advance Flamingo's RNA-targeting oncology portfolio, including translational research for its lead clinical program, danvatirsen in Phase II in head and neck squamous cell carcinoma, and preclinical work on its long non-coding RNA (LncRNA) program targeting MALAT-1.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Gaston Geenslaan 1
Leuven, 3001
Belgium
Leuven, 3001
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Our company was built upon our deep experience and know-how in RNA therapeutics and we are well-positioned to advance candidates against targets considered "undruggable", using RNA chemistries. We are focused on advancing our clinical pipeline for large unmet oncology indications where we believe RNA-targeting can be successful.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stéphane Rooijen
Chief Medical Officer
Andrew Denker
Co-Founder
Floor Stam
Vice President
Mark Gidjunis
Browse more venture capital transactions:
Prev: 6/16/2023: Fastned venture capital transaction
Next: 6/17/2023: Eavor Technologies venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs